#CDK46

Article titled: Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer—The Sooner, the Better? by Carmine Valenza, MD, MPH; Harold J. Burstein, MD, PhD. It discusses the SONIA study's findings on first-line CDK4/6i.

💬Editorial: SONIA demonstrates that reserving #CDK46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #BreastCancer, supporting individualized sequencing and shared decision-making.

ja.ma/3ZAACFp

CDK4/6i resistance in HR+/HER2− BC
✅ Explores mechanisms: cell cycle dysregulation, signaling pathway changes
✅ Strategies: switching CDK4/6 drugs, novel endocrine combos, targeted therapy
Read more 👉 buff.ly/TNQGgFD
#BreastCancer #CDK46 #Oncology #DrugResistance

Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer - Marya Hussain, Christine Brezden-Masley, Stephen Chia, Giuseppe Curigliano, Marc Webster, Jan-Willem Henning, 2025 The introduction of the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib to the adjuvant setting marks a significant advancement ...

CDK4/6 inhibitors are making waves in early breast cancer care. This guide explores how abemaciclib & ribociclib are being integrated into adjuvant therapy for HR+, HER2− EBC - plus tips on managing side effects & improving adherence.
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46

#PublicaSalutIB 💉👩 Son Llatzer participa en un estudi on s'analitzen les comorbiditats en càncer de mama metastàtic HR+/HER2- amb CDK4/6 www.infosalut.com/investigacio/estudis-i-p...
https://doi.org/10.1016/j.clbc.2024.12.016

#càncerdemama #càncerdemamametastàtic #HER2 #CDK46

#PublicaSalutIB 💉👩 Son Llatzer participa en un estudio donde se analizan las comorbilidades en cáncer de mama metastático HR+/HER2- con CDK4/6 https://www.infosalut.com/es/17267 https://doi.org/10.1016/j.clbc.2024.12.016

#cáncerdemama #cáncerdemamametastático #HER2 #CDK46

#PublicaSalutIB 💉👩 Son Llatzer participa en un estudi on s'analitzen les comorbiditats en càncer de mama metastàtic HR+/HER2- amb CDK4/6 www.infosalut.com/investigacio/estudis-i-p... https://doi.org/10.1016/j.clbc.2024.12.016

#càncerdemama #càncerdemamametastàtic #HER2 #CDK46

🚨 Big news! 🚨 Our lab's latest paper by Jamil Nehme (@jamilnehme.bsky.social) is out now:
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer.
Check it out! (doi.org/10.1038/s443...) Congrats, Jamil! #CancerResearch #CDK46 #BreastCancer